There is 1 paper on retinal AI risk score in aging research: 1 observational study in people.
1 paper studies it2 findings
1 new paper in 30 daysSee all 1 papers on retinal AI risk score
“the very high retinal AI risk group independently predicted ASCVD (SCORE2-adjusted HR 2.32 vs low risk; p<0.001).”
- Humans1
Effects
1Risk reclassification across the ESC/EAS statin-indication boundary
upin humans1
1 study
Risk reclassification across the ESC/EAS statin-indication boundary
upin humans1
Retinal AI risk score is linked with better risk reclassification across the ESC/EAS statin-indication boundary in humans (Adding the retinal AI risk score to SCORE2 in statin-naive participants without diabetes) (Statin-eligibility NRI 0.012, p<0.001; continuous NRI 0.445, p<0.001; no C-index or net-benefit gain).
“Adding the retinal AI risk score to SCORE2 reclassified risk across the ESC/EAS statin-indication boundary (statin-eligibility NRI [net reclassification improvement] 0.012, p<0.001)”
HumansAdding the retinal AI risk score to SCORE2 in statin-naive participants without diabetes10-year predictionn = 40,672
European journal of preventive cardiology
Associations
1Atherosclerotic cardiovascular disease
upin humans1HR 2.32
1 study
Atherosclerotic cardiovascular disease
upin humans1HR 2.32
Retinal AI risk score predicts atherosclerotic cardiovascular disease in humans (SCORE2-adjusted HR 2.32 versus low risk; p<0.001).
“the very high retinal AI risk group independently predicted ASCVD (SCORE2-adjusted HR 2.32 vs low risk; p<0.001).”
HumansStatin-naive participants without diabetes; very high versus low retinal AI risk, adjusted for SCORE210.0-year median follow-upn = 40,672
European journal of preventive cardiology